<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332393</url>
  </required_header>
  <id_info>
    <org_study_id>21-20POR</org_study_id>
    <nct_id>NCT04332393</nct_id>
  </id_info>
  <brief_title>Metformin to Treat Corticosteroids-induced Hyperglycemia</brief_title>
  <official_title>The Effect of Metformin in Pregnant Women Who Received Antenatal Corticosteroids on Glycemic Control and the Rate of Neonatal Hypoglycemia - Multicenter Prospective Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Baruch Padeh Medical Center, Poriya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Baruch Padeh Medical Center, Poriya</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antenatal corticosteroids, particularly, betamethasone is routinely administered to pregnant
      women at risk for preterm delivery to improve neonatal outcomes.

      Although antenatal betamethasone was shown to induce both maternal hyperglycemia and neonatal
      hypoglycemia, to date, there is insufficient data to establish whether treatment for maternal
      hyperglycemia, particularly, metformin, will decrease the risk for neonatal hypoglycemia,
      particularly of preterm neonates.

      In the present study the investigators will examine the effect of treatment with metformin on
      maternal glycemic control and hypoglycemia in preterm neonates following maternal
      betamethasone treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean maternal daily glucose values</measure>
    <time_frame>Up to 4 days</time_frame>
    <description>According to daily glucose charts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of neonatal hypoglycemia in preterm deliveries (&lt;37 gestational weeks)</measure>
    <time_frame>Up to 7 days after delivery or discharge (which ever comes first)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean maternal daily pre-prandial glucose values</measure>
    <time_frame>Up to 4 days</time_frame>
    <description>According to daily glucose charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean maternal daily post-prandial glucose values</measure>
    <time_frame>Up to 4 days</time_frame>
    <description>According to daily glucose charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of abnormal values in the daily glucose chart</measure>
    <time_frame>Up to 4 days</time_frame>
    <description>According to daily glucose charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cesarean sections and operative deliveries</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of neonates who will be admitted to the neonatal intensive care unit</measure>
    <time_frame>Up to a week after delivery</time_frame>
    <description>APGAR scale of 0-worst and 10-best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score at 1 and 5 minutes</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cord blood pH levels (when taken)</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of neonates with hyperbilirubinemia</measure>
    <time_frame>Up to 7 days after delivery or discharge (which ever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mean head circumference</measure>
    <time_frame>Up to 7 days after delivery or discharge (which ever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mean birth weight</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of fetal malformations and developmental disorders</measure>
    <time_frame>Up to 7 days after delivery or discharge (which ever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and lowest neonatal blood glucose values in preterm neonates</measure>
    <time_frame>Up to 7 days after delivery or discharge (which ever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of maternal adverse effects</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">323</enrollment>
  <condition>Pregnancy Preterm</condition>
  <condition>Glycemic Control</condition>
  <condition>Corticosteroids Induced Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin tablets according to glycemic control. Initial dose: 425 mg before meals (breakfast, lunch and supper) and 850 mg around 22:00. Modifications may take place according to glycemic control</description>
    <arm_group_label>metformin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women receiving betamethasone from 24 to 36.5 gestational weeks

          -  Before or within 24 hours following the first dose of betamethasone

          -  â‰¥18 years old

        Exclusion Criteria:

          -  Women with pre-gestational and gestational diabetes mellitus (GDM)

          -  Known allergic sensitivity to metformin

          -  Known chronic heart failure

          -  Known chronic renal failure

          -  Refuse to participate

          -  Refuse to perform glucose challenge test/glucose tolerance test later on
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enav Yefet, MD/PhD</last_name>
    <phone>972-46652306</phone>
    <email>enyefet@poria.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baruch Padeh Medical center, Poriya</name>
      <address>
        <city>Tiberias</city>
        <state>North</state>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enav Yefet, MD/PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>May 17, 2020</last_update_submitted>
  <last_update_submitted_qc>May 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared according to the local review board regulations</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

